Anzeige
Mehr »
Mittwoch, 30.07.2025 - Börsentäglich über 12.000 News
Geheime Millionen-Käufe in Bitcoin & Altcoins - ohne Wallet, ohne Risiko? Jetzt wird's spannend
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EMJP | ISIN: US52187K2006 | Ticker-Symbol: 5MC
Tradegate
30.07.25 | 16:05
0,294 Euro
+2,08 % +0,006
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
LEAP THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
LEAP THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,2820,30822:36
0,2680,30022:00

Aktuelle News zur LEAP THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
23.06.Leap Therapeutics stock jumps after announcing strategic review process6
23.06.Leap Therapeutics Initiates Process To Explore Strategic Options6
LEAP THERAPEUTICS Aktie jetzt für 0€ handeln
23.06.Leap Therapeutics explores strategic options amid colorectal cancer drug data1
23.06.LEAP THERAPEUTICS, INC. - 8-K, Current Report-
23.06.Leap Therapeutics, Inc.: Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic Alternatives121Updated data from DeFianCe study continue to demonstrate statistically significant improvements in PFS among the DKK1 -high, VEGF-naïve and liver metastasis subgroups...
► Artikel lesen
13.05.Leap Therapeutics GAAP EPS of -$0.378
13.05.Leap Therapeutics, Inc. (LPTX) Q1 Loss Beats Estimates7
13.05.LEAP THERAPEUTICS, INC. - 8-K, Current Report2
13.05.Leap Therapeutics, Inc.: Leap Therapeutics Reports First Quarter 2025 Financial Results680CAMBRIDGE, Mass., May 13, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology...
► Artikel lesen
13.05.LEAP THERAPEUTICS, INC. - 10-Q, Quarterly Report2
27.03.H.C. Wainwright maintains neutral on Leap Therapeutics stock10
26.03.LEAP THERAPEUTICS, INC. - S-8, Securities to be offered to employees in employee benefit plans5
26.03.Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer5
26.03.Leap Therapeutics, Inc.: Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results330Leap to host a conference call to present updated CRC clinical data today, March 26, 2025, at 8:00 a.m. ET CAMBRIDGE, Mass., March 26, 2025 /PRNewswire/ --...
► Artikel lesen
26.03.Leap Therapeutics, Inc.: Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study384Updated data confirms statistically significant 32% higher ORR and 3.5 month longer PFS in second-line CRC patients with high DKK1 levels treated with sirexatamab...
► Artikel lesen
26.03.Leap Therapeutics GAAP EPS of -$0.37 misses by $0.015
26.03.LEAP THERAPEUTICS, INC. - 10-K, Annual Report1
26.03.LEAP THERAPEUTICS, INC. - 8-K, Current Report2
17.03.LEAP THERAPEUTICS, INC. - 8-K, Current Report3
28.01.Leap Therapeutics, Inc.: Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study17835% objective response rate (ORR) in second-line colorectal cancer (CRC) patients treated with sirexatamab (DKN-01) plus bevacizumab and chemotherapy, compared to...
► Artikel lesen
Weiter >>
22 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1